news.google.com

“Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial.” F. Torres, H. Farber, A. Ristic, et al. Eur Respir J 2019; 54: 1901030. - ERS

Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.